Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0002058093-26-000004·ArriVent BioPharma, Inc.
Schedule 13G ownership disclosure
ArriVent Biopharma Inc
Common Stock · CUSIP: 04272N102
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- INFINITUM ASSET MANAGEMENT, LLC
Shares: 4,123,923.00 · Class: 9.9%
- Infinitum Partners GP, LLC
Shares: 4,123,923.00 · Class: 9.9%
- Infinitum Cayman Master, Ltd.
Shares: 4,123,923.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002058093-26-000004
- Form type
- SCHEDULE 13G/A
- Filer
- ArriVent BioPharma, Inc.
- CIK
- CIK 1868279
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership